The investment will expand Resilience’s U.S. capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.

Ziltivekimab’s failure in a key trial spurred share sell-offs for Novo and other biotechs, as it suggested trouble for different cardiovascular drugs that also target inflammation.

​Read More

In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kong Exchange rather than a U.S. market. We dig into the company’s reasoning. Then we turn our attention to Latigo’s report of positive Phase IIb data for its non-opioid acute pain candidate, and its plans to go through a planned IPO soon. Switching to some science news, we discuss findings from a study that identified genetic risk factors for fibromyalgia syndrome as well as links to other neurodegenerative, autoimmune, and metabolic diseases. And lastly, a potential base editing therapy for Huntington’s disease that has shown promise in mice.

Listed below are links to the GEN stories referenced in this episode of Touching Base:

StockWatch: Axiom CEO Explains Plans for Hong Kong IPO 
By Alex Philippidis, GEN Edge, July 27, 2026

Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate
By Alex Philippidis, GEN Edge, July 30, 2026

Genetic Study of Fibromyalgia Points to Neurological Basis 
GEN, July 29, 2026

Base Editing Strategy Alleviates Huntington’s Disease in Mice 
GEN, July 29, 2026

Touching Base Podcast
Hosted by Corinna Singleman, PhD

Behind the Breakthroughs
Hosted by Jonathan D. Grinstein, PhD

The State of Biologics Testing 2026
Charles River Laboratories and GEN, June 10, 2026

The post Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s appeared first on GEN – Genetic Engineering and Biotechnology News.